IBSA Institut Biochimique v. Accord Healthcare: Levothyroxine Patent Dispute Settles After 978 Days
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | IBSA Institut Biochimique, S.A. et al. v. Accord Healthcare, Ltd. |
| Case Number | 2:23-cv-00054 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Jan 2023 – Sep 2025 978 days / 32 months |
| Outcome | Settlement Reached – Confidential Terms |
| Patents at Issue | |
| Accused Products | Generic Levothyroxine Sodium Oral Solution (12 dosage strengths) |
Case Overview
The Parties
⚖️ Plaintiff
Swiss biopharmaceutical group focused on drug formulation and delivery innovation, holding proprietary thyroid therapy formulations.
🛡️ Defendant
Global generic pharmaceutical manufacturer known for filing Abbreviated New Drug Applications (ANDAs) challenging branded drug patents across therapeutic categories.
Patents at Issue
This landmark case involved three U.S. patents covering levothyroxine sodium oral solution formulations:
- • US 11,241,382 B2 — Levothyroxine sodium oral solution formulation
- • US 10,537,538 B2 — Levothyroxine sodium oral solution formulation
- • US 11,096,913 B2 — Levothyroxine sodium oral solution formulation
Developing a new drug formulation?
Check if your formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The court reported that the action was settled by agreement of the parties. No trial verdict was rendered, no damages award was issued, and no injunctive relief was judicially imposed. The specific terms of the settlement — including any licensing arrangement, authorized generic agreement, market entry date concessions, or financial consideration — were not disclosed in the public record, which is standard practice in pharmaceutical patent settlements.
Key Legal Issues
The case reflects a well-established pattern in pharmaceutical patent litigation: branded drug manufacturers leveraging layered patent portfolios to deter or delay generic market entry, ultimately reaching negotiated resolution before trial. This outcome is common in ANDA-related disputes governed by the Hatch-Waxman Act.
Drafting pharmaceutical patents?
Learn from this case. Use AI to draft stronger claims for drug formulations that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis for Pharmaceutical Formulations
This case highlights critical IP risks in specialty pharmaceutical formulation design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in levothyroxine oral solution space
- See which companies are most active in formulation patents
- Understand ANDA litigation patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your drug formulation or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Oral solution drug formulations
3 Asserted Patents
In levothyroxine oral solution space
Strategic Settlement
Common outcome for pharma disputes
✅ Key Takeaways
For Patent Attorneys
Layered portfolio prosecution across formulation, method, and process claims creates strong litigation barriers and negotiation leverage.
Search related case law →The District of New Jersey remains a key venue for Hatch-Waxman disputes, with settlements common before trial in complex pharma cases.
Explore precedents →For R&D Teams
Liquid formulation development for existing active pharmaceutical ingredients (APIs) entering new dosage forms carries substantial patent risk; FTO analysis is crucial.
Start FTO analysis for my product →Consider filing patents early for alternative drug delivery forms to extend market exclusivity and strengthen IP strategy.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.